A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Edwin M. Posadas,Mourad Tighgohart,Yi-Tsung Lu,Dolores Di Vizio,David M. J. Hoffman,Leland Green,Margarit Sievert,Amy Oppenheim,Nancy P. Moldawer,Beatrice S. Knudsen,Michael R. Freeman,Neil A. Bhowmick,Andre Rogatko,Hsian-Rong Tseng,Leland W.K. Chung,Robert A. Figlin

A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.

2014

Edwin M. Posadas
Mourad Tighgohart
Yi-Tsung Lu
Dolores Di Vizio
David M. J. Hoffman
Leland Green
Margarit Sievert
Amy Oppenheim
Nancy P. Moldawer
Beatrice S. Knudsen
Michael R. Freeman
Neil A. Bhowmick
Andre Rogatko
Hsian-Rong Tseng
Leland W.K. Chung
Robert A. Figlin

e16080 Background: Cabozantinib (XL184) is a potent multi-targeted tyrosine kinase inhibitor (TKI) that is under active investigation in several malignancies including prostate cancer (PC). The mec...

Keywords:

Phases of clinical research
Cancer research
Circulating tumor cell
Pathology
Castration
Prostate cancer
Cabozantinib
Medicine
Tyrosine-kinase inhibitor
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations